| Literature DB >> 14717228 |
Moo Suk Park1, Dong Hwan Shin, Kyung Young Chung, Jae Hee Cheong, Jae Ho Chung, Do Hoon Kim, Se Kyu Kim, Joon Chang, Joo Hang Kim, Sung Kyu Kim, Young Sam Kim.
Abstract
BACKGROUND: To define the final outcome of large cell carcinomas (LCC) after surgical treatment, the histopathology, clinical features and follow-up results of 28 cases were reviewed.Entities:
Mesh:
Year: 2003 PMID: 14717228 PMCID: PMC4531643 DOI: 10.3904/kjim.2003.18.4.212
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 2.884
Frequency of primary and surgically resected primary lung cancers, by histologic types, at the Severance Hospital during the 15 year period (1986–2001)
| Histologic type | All primary lung ca | Surgically resected primary lung ca |
|---|---|---|
| Adenocarcinoma | 1,456 (28.7%) | 268 (27.0%) |
| Bronchioloalveolar cell carcinoma | 129 (2.5%) | 67 (6.7%) |
| Squamous cell carcinoma | 2,230 (44.0%) | 523 (52.0%) |
| Small cell carcinoma | 770 (15.2%) | 14 (1.4%) |
| Large cell carcinoma | 85 (1.7%) | 29 (2.9%) |
| Giant cell carcinoma | 11 (0.2%) | 3 (0.3%) |
| Large cell neuroendocrine carcinoma | 18 (0.4%) | 7 (0.7%) |
| Carcinoid | 13 (0.3%) | 9 (0.9%) |
| Mucoepidermoid carcinoma | 10 (0.2%) | 6 (0.6%) |
| Adenoid cystic carcinoma | 8 (0.2%) | 4 (0.4%) |
| Adenosquamous cell carcinoma | 49 (1.0%) | 27 (2.7%) |
| Others and unspecified carcinoma | 279 (5.5%) | 40 (4.0%) |
| Sarcoma | 6 (0.1%) | 1 (0.1%) |
| Mesothelioma | 1 (0.0%) | 1 (0.1%) |
| Miscellaneous | 4 (0.1%) | 4 (0.4%) |
|
| ||
| Total | 5,069 (100.0%) | 1,003 (100.0%) |
Clinical features of large cell carcinomas, 28 cases
| Case | Sex | Age | Smoking (PY) | FOB/TBLB
| FNAB | Preop-pathol | Preop-staging | Postop-staging | Op-name | CTx | RTx | Follow up | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bx | Cyto | ||||||||||||
| 1 | M | 45 | 20 | N | N | N | N | T1N2M0 (IIIA) | T1N2M0 (IIIA) | MR | adj | adj | Alive (74 mon) |
| 2 | M | 41 | 0 | T | T2N2M0 (IIIA) | T2N2M0 (IIIA) | P | adj | adj | Alive (45 mon) | |||
| 3 | M | 67 | 60 | F | N | Squam | T2N1M0 (IIB) | T2N0M0 (IB) | P | N | N | Alive (86 mon) | |
| 4 | M | 57 | 40 | F | Squam | T2N2M0 (IIIA) | T2N0M0 (IB) | P | N | N | Alive (101 mon) | ||
| 5 | M | 61 | 30 | F | NSCLC | T3N1M0 (IIIA) | T2N1M0 (IIB) | P | adj | adj | Alive (939 mon) | ||
| 6 | M | 44 | 30 | T | N | T2N0M0 (IB) | T2N0M0 (IB) | L | adj | adj | Alive (42 mon) | ||
| 7 | M | 52 | 45 | F | N | Adeno | T2N2M0 (IIIA) | T2N0M0 (IB) | BL | adj | N | Alive (114 mon) | |
| 8 | M | 57 | 40 | F | NSCLC | T1N0M0 (IA) | T1N0M0 (IA) | P | N | N | Alive (61 mon) | ||
| 9 | M | 64 | 45 | T | Squam | T2N1M0 (IIB) | T2N0M0 (IB) | L | N | N | Alive (3 mon) | ||
| 10 | M | 68 | 0 | T | N | Adeno | T2N0M0 (IB) | T2N1M0 (IIB) | L | adj | adj | Died | |
| 11 | M | 64 | 0 | F | N | Squam | T4N2M0 (IIIB) | T3N0M0 (IIB) | P | N | adj | Died | |
| 12 | M | 72 | 50 | F | Adeno | T3N2M0 (IIIA) | T2N2M0 (IIIA) | L | adj | adj | Died | ||
| 13 | M | 59 | 50 | F | Squam | T4N2M0 (IIIB) | T3N1M0 (IIIA) | P | adj | a+p | Died | ||
| 14 | M | 75 | 30 | T | Squam | T3N0M0 (IIB) | T3N0M0 (IIB) | L | N | N | Died | ||
| 15 | M | 72 | 50 | N | N | Squam | T3N0M0 (IIB) | T3N0M0 (IIB) | L | N | adj | Died | |
| 16 | M | 70 | 25 | F | Adeno | T2N0M0 (IB) | T2N0M0 (IB) | L | N | N | Died | ||
| 17 | F | 61 | 7 | T | NSCLC | T2N2M0 (IIIA) | T2N2M0 (IIIA) | P | N | N | Died | ||
| 18 | F | 42 | 0 | T | N | Adeno | T2N2M0 (IIIA) | T2N0M0 (IB) | BL | N | N | Alive (35 mon) | |
| 19 | M | 62 | 60 | F | N | T4N3M0 (IIIB) | T3N0M0 (IIB) | P | N | adj | Alive (41 mon) | ||
| 20 | M | 43 | NR | F | NSCLC | T4N2M0 (IIIB) | T2N0M0 (IB) | L | N | pall | Died | ||
| 21 | M | 56 | 40 | F | Squam | T4N2M0 (IIIB) | T4N2M1 (IV) | P | adj | N | Alive (49 mon) | ||
| 22 | M | 58 | 40 | F | NSCLC | T3N2M0 (IIIA) | T3N1M0 (IIIA) | P | adj | N | Died | ||
| 23 | M | 64 | 40 | F | Squam | T4N0M0 (IIIB) | T3N1M0 (IIIA) | P | N | adj | Died | ||
| 24 | M | 65 | 45 | T | N | NSCLC | T2N2M0 (IIIA) | T2N0M0 (IB) | P | N | N | F/U loss | |
| 25 | F | 63 | NR | F | N | Adeno | T3N2M0 (IIIA) | T3N0M0 (IIB) | BL | N | N | F/U loss | |
| 26 | M | 56 | 40 | F | NSCLC | T2N0M0 (IB) | T2N0M0 (IB) | L | N | N | F/U loss | ||
| 27 | M | 63 | 30 | F | N | T4N2M0 (IIIB) | T3N0M0 (IIB) | L | N | N | F/U loss | ||
| 28 | M | 60 | 40 | T | N | Lcca | T2N0M0 (IB) | T2N0M0 (IB) | P | N | N | Alive (143 mon) | |
Abbreviations: Adeno, adenocarcinoma; adj, adjuvant; a+p, adjuvant + palliative; BL, bilobectomy; Bx, biopsy; CTx, chemotherapy; Cyto, washing cytology; FNAB, fine needle aspiration biopsy; FOB (F), fiberoptic bronchoscopy; L, lobectomy; Lcca, large cell carcinoma; mon, months; MR, mass resection; N, not performed; NSCLC, non-small cell lung carcinoma; Op, operation; P, pneumonectomy; pall, palliative; PY, pack year; RTx, radiation therapy; Squam, squamous cell carcinoma; TBLB (T), transbronchial luhg biopsy;
negative;
positive;
died of neoplastic disease
Clinical Symptoms
| Symptoms | No. of patients |
|---|---|
| Cough | 19 (68.0%) |
| Sputum | 15 (54.0%) |
| Chest pain | 11 (39.0%) |
| Hemoptysis | 11 (39.0%) |
| Dyspnea | 5 (18.0%) |
| Weight loss | 5 (18.0%) |
| Asymptomatic | 2 (7.0%) |
| Chest wall mass | 1 (3.5%) |
Malignancy rate of preoperative diagnostic methods
| Methods | No. of patients | Malignancy diagnosis rate |
|---|---|---|
| Fine needle aspiration biopsy | 16 | 14 (88%) |
| Fiberoptic bronchoscopy | 26 | 10 (38%) |
| - Visible mass | 10 | 5 (50%) |
| - No visible mass | 7 | 0 (0%) |
| - TBLB | 9 | 5 (55%) |
| Bronchial washing | 26 | 9 (35%) |
| Non-diagnostic | 5 | 0 (0%) |
One case was diagnosed by both TBLB and FNAB.
Abbreviations: TBLB, transbronchial lung biopsy
Preoperative diagnostic methods and cell types
| Cell type
| FOB | FNAB | Total |
|---|---|---|---|
| Dx methods | |||
| Adenocarcinoma | 4 (40%) | 2 (14%) | 6 (25%) |
| Squamous cell carcinoma | 3 (30%) | 7 (50%) | 10 (42%) |
| NSCLC unknown type | 2 (20%) | 5 (36%) | 7 (29%) |
| Large cell carcinoma | 1 (10%) | 0 (0%) | 1 (4%) |
|
| |||
| Total | 10 (100%) | 14 (100%) | 24 (100%) |
One case was diagnosed by both TBLB and FNAB, with 23 real cases of preoperative diagnosis of lung cancer.
Abbreviations: FNAB, fine needle aspiration biopsy; FOB, fiberoptic bronchoscopy; NSCLC, non-small cell lung carcinoma
Comparison between preoperative chest CT scan and postoperative pathology for hilar and mediastinal lymph node infiltration
| Pathology | Chest CT findings
| |||
|---|---|---|---|---|
| N1 nodes | N2 nodes | |||
|
| ||||
| (+) | (−) | (+) | (−) | |
| (+) | 1 | 4 | 5 | 0 |
| (−) | 3 | 20 | 11 | 12 |
N1 nodes sensitivity 20%, specificity 87%, accuracy 75%, N2 nodes sensitivity 100%, specificity 52%, accuracy 61%, N1 & N2 nodes sensitivity 60%, specificity 70%, accuracy 68%
Comparision of preoperative and postoperative stages
| Preop. stage | Postoperative stage
| |||||||
|---|---|---|---|---|---|---|---|---|
| IA | IB | IIA | IIB | IIIA | IIIB | IV | Total | |
| IA | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| IB | 0 | 4 | 0 | 1 | 0 | 0 | 0 | 5 |
| IIA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IIB | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 4 |
| IIIA | 0 | 4 | 0 | 2 | 5 | 0 | 0 | 11 |
| IIIB | 0 | 1 | 0 | 3 | 2 | 0 | 1 | 7 |
| Total | 1 | 11 | 0 | 8 | 7 | 0 | 1 | 28 |
Stage concordance 12/28 (43%)
Up staged 2 cases, down staged 14 cases
Figure 1.Survival of surgically resected a large cell carcinoma in 28 cases
Comparison of clinical features and surgical treatment outcomes of large cell carcinomas
| Author (published year) | Mitchel et al[ | Downey et al[ | Downey[ | This study |
|---|---|---|---|---|
| Study durations (year) | 1968 – 1978 | 1973 – 1983 | 1982 – 1986 | 1986 – 2001 |
| Subjects | All LCC | All LCC | Surgically resected LCC | Surgically resected LCC |
| Total No. of LCC (% of all lung cancer) | 208 (9.0) | 96 (6.7) | NR | 85 (1.7) |
| Surgically resected cases (% of all LCC) | 59 (28.4) | 13 (13.3) | 61 (NR) | 28 (32.9) |
| Centrality of mass (%) | Peripheral (43) | NR | NR | Peripheral (54) |
| Smoker (%) | 95 | 96 | 98 | 85 |
| Most common Symptom (%) | Cough (61.5) | Cough (22.0) | Cough (38.0) | Cough (68.0) |
| FOB biopsy Dx rate (%) | 87/208 (42) | 35/96 (37) | 23/42 (55) | 10/28 (36) |
| Sputum cytology Dx rate (%) | 29/208 (14) | NR | 4/31 (13) | 1/25 (4) |
| Postoperative stage (%) | I, II 46 (78.0) | I 6 (46.1) | I, II 37 (61.0) | I, II 20 (71.4) |
| III 13 (22.0) | III 5 (38.5) | III 22 (36.0) | III 7 (25.0) | |
| IV 2 (15.4) | IV 2 (3.0) | IV 1 (3.6) | ||
| Surgery and other treatment modality (%) | Sur 55 (93.2) | Sur 9 (69.2) | NR | Sur 13 (46.4) |
| Sur+RTx 4 (6.8) | Sur+RTx 4 (30.8) | Sur+RTx 5 (17.9) | ||
| Sur+CTx 3 (10.7) | ||||
| Sur+CTx+RTx 7 (25.0) | ||||
| Median survival of surgically resected patients (months) | 13.0 | Overall 15.9 | NR | 54.5 |
| 5-year survival of surgically resected patients (%) | 21.2 | Unable | NR | 45.0 |
Abbreviations: CTx, chemotherapy; Dx, diagnosis; FOB, fiberoptic bronchoscopy; LCC, large cell carcinoma; NR, not reported; RTx, radiotherapy; Sur, surgery
Chest CT scan and pathologic findings in 28 cases of a large cell carcinoma
| Case | CT finding | Pathologic finding | ||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| No. | Centrality | Mass locationz | Mass size (cm) | Mass margin | Internal low density | Lymphadenopathy | Necrosis | Lymphadenopathy |
| 1 | central | RUL | 8 * 8 | lobulated | Yes | PT | Yes | PT |
| 2 | peripheral | RLL | 6 * 5 | smooth | Yes | SC, PT | Yes | SC, PT |
| 3 | peripheral | RLL | 3.5 * 3.5 | smooth | Yes | H | Yes | N0 |
| 4 | central | LLL | 6 * 6 | lobulated | Yes | PA | Yes | N0 |
| 5 | central | LLL | 7 * 7 | lobulated | Yes | H | Yes | IP |
| 6 | peripheral | LUL | 4 * 3 | lobulated | Yes | No | Yes | N0 |
| 7 | central | RLL | 4 * 4 | lobulated | Yes | SC, PT | Yes | N0 |
| 8 | peripheral | RML | 1.5 * 2 | smooth | No | No | Yes | N0 |
| 9 | peripheral | RLL | 5 * 5.5 | lobulated | Yes | H | Yes | N0 |
| 10 | peripheral | RUL | 3 * 3 | lobulated | Yes | No | Yes | IP |
| 11 | central | RLL | 6.5 * 4 | lobulated | Yes | PT, SC | Yes | N0 |
| 12 | peripheral | RML | 4.5 * 5 | lobulated | Yes | SC, PT | Yes | PT |
| 13 | central | LUL | 4 * 3.5 | lobulated | Yes | PA | Yes | H |
| 14 | peripheral | RUL | 4 * 4 | spiculated | Yes | No | Yes | N0 |
| 15 | central | RUL | 5 * 5 | spiculated | Yes | No | Yes | N0 |
| 16 | peripheral | LLL | 4 * 4 | lobulated | Yes | No | Yes | N0 |
| 17 | peripheral | LLL | 5.5 * 3.5 | lobulated | Yes | PA,PT | Yes | PA |
| 18 | central | RLL | 6.5 * 6 | spiculated | Yes | H, SC | Yes | N0 |
| 19 | central | RUL | 8 * 6 | lobulated | Yes | PT, SCLN | Yes | N0 |
| 20 | central | RUL | 9 * 5 | lobulated | Yes | PA, SC | Yes | N0 |
| 21 | peripheral | RLL | 6 * 5 | lobulated | Yes | PT | Yes | PT |
| 22 | central | LUL | 15 * 11 | lobulated | Yes | PA | Yes | H |
| 23 | peripheral | LLL | 12 * 10 | lobulated | Yes | No | Yes | IP |
| 24 | peripheral | LLL | 3 * 3 | lobulated | Yes | PA | Yes | N0 |
| 25 | central | RLL | 3 * 2 | lobulated | No | SC | No | N0 |
| 26 | peripheral | RUL | 7 * 6 | lobulated | Yes | No | Yes | N0 |
| 27 | central | LUL | 5 * 4 | spiculated | Yes | PA | Yes | N0 |
| 28 | peripheral | RLL | 4 * 3 | spiculated | Yes | No | Yes | N0 |
Abbreviations: H, hilar; PA, preaortic; PT, paratracheal; SC. subcarina; SCLN, supraclavicular lymph node